Investor Presentaiton
C> Continues to be a Significant Growth Opportunity
C> Pipeline by Phase: ~3,300 Active Programs
~20*
Therapies approved by FDA today
total
83
13%
■ Preclin
Ph 1 ■ Ph 2
■Ph 3 ■Pre-Reg
67 493
10%
NUT
449
375
18%
58
364
407
57
287
371
59
60 309
226
56267
2,206
24%
200
1,968
255
171
45
154
1,476
229
40
29 37
1,156
22
171
150
84
71
202
123
175
901
82
88
99
782
663
461
808
-15%
10-20
per year
C> approvals expected
per year by 2025
of biopharma R&D pipelines
are C> programs
>2/3
of programs in preclinical phase,
setting the stage for sustained growth
2,700+ C> developers worldwide
287 321 311 325
2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022
CAGR
2019-22**
Charles River Laboratories (CRL)
$12.6B
Funding for C> companies
in FY 2022
Source: FDA, Alliance for Regenerative Medicine, PricewaterhouseCoopers, PharmaProjects, Citeline, SVB.
* Excludes cell transplantation and cell-based regenerative medicine products.
19View entire presentation